Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and have approved submission.
Research funding: This work was supported by the Kerckhoff Heart Research Institute together with the Justus Liebig University (KHFI). The BioProspective study cohort was funded by the German Centre for Cardiovascular Research (DZHK) and the William G. Kerckhoff Stiftung, Bad Nauheim, Germany.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T. Annals of internal medicine review meta-analysis : diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797–808.10.7326/0003-4819-146-11-200706050-00008Search in Google Scholar PubMed
2. Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013;228:243–6.10.1016/j.atherosclerosis.2013.02.009Search in Google Scholar PubMed
3. Hwang SM, Kim JO, Yoo YM, Shin S, Kim JQ, Park MH, et al. Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis. Clin Chem Lab Med 2010;48:225–30.10.1515/CCLM.2010.046Search in Google Scholar PubMed
4. Hermans MP, van der Velden D, Montero Cabezas JM, Putter H, Huizinga TW, Kuiper J, et al. Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. Int J Cardiol 2017;240:20–4.10.1016/j.ijcard.2017.04.046Search in Google Scholar PubMed
©2018 Walter de Gruyter GmbH, Berlin/Boston
